Compare Cenovus Energy Inc (CVE) vs Cytokinetics Inc (CYTK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cenovus Energy Inc vs Cytokinetics Inc — how do they compare? Cenovus Energy Inc trades at $27.59 (market cap $50.90B), while Cytokinetics Inc trades at $81.99 (market cap $11.12B). The key difference: Cenovus Energy Inc is far larger — about 4.6× Cytokinetics Inc's market cap, and Cenovus Energy Inc pays a 2.25% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals.
| CVE | CYTK | |
|---|---|---|
Market Cap | $50.90B | $11.12B |
Sector | Energy | Technology |
52-Week High | $31.80 | $87.26 |
52-Week Low | $13.96 | $33.23 |
Enterprise Value | $58.77B | $11.59B |
Dividend Yield | 2.25% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cenovus Energy (CVE) trades at $27.61, up 4.58% with strong bullish technical indicators and consistent earnings beats. The stock shows solid fundamentals with a P/E of 15.62, ROE of 14.86%, and improving cash flow projections. Recent news highlights benefits from rising crude prices and operational synergies from MEG Energy acquisition.
CVE presents a compelling investment case with attractive valuation, strong profitability metrics, and positive analyst sentiment (40.74% buy ratings). Key risks include oil price volatility and execution challenges in growth projects. The integrated business model provides resilience across energy cycles.
CYTK trades at $82.24, down 3.1% today, with a bullish technical outlook supported by moving averages and RSI near oversold levels. The company shows strong analyst support with 97% buy ratings and a $110.40 consensus target, but faces fundamental challenges with a -784% net income margin and negative cash flow from operations of -$510M in 2025. Recent positive developments include FDA approval and European launch of Myqorzo, driving commercial momentum.
Outlook remains speculative with high valuation (P/S 93.92) against significant losses, yet growth potential exists if Myqorzo gains market traction. Key risks include cash burn, competitive pressure, and reliance on single drug success. Institutional sentiment is overwhelmingly bullish, but investors must weigh high risk-reward profile amid ongoing profitability challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cenovus Energy Inc
Cenovus Energy is an integrated oil company, focused on creating value through the development of its oil sands assets. The company also engages in production of conventional crude oil, natural gas liquids, and natural gas in Alberta, Canada, with refining operations in the U.S. Net upstream production averaged 472 thousand barrels of oil equivalent per day in 2020, and the company estimates that it holds 6.7 billion boe of proven and probable reserves.
Read more on CVE →About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →
